Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Contract Assets and Liabilities (Details)

v3.21.2
Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Contract with Customer, Asset, Net [Abstract]    
Current pharma contract assets $ 1,903 $ 1,643
Long-term pharma contract assets 248 290
Total pharma contract assets 2,151 1,933
Capitalized Contract Cost [Abstract]    
Current pharma capitalized commissions 126 185
Long-term pharma capitalized commissions 953 970
Total pharma capitalized commissions 1,079 1,155
Contract with Customer, Liability [Abstract]    
Current pharma contract liabilities 5,278 4,029
Long-term pharma contract liabilities 932 712
Total pharma contract liabilities $ 6,210 $ 4,741